MDR-TB in children: back to the basics

Post Date: 
2018-05-01
   |   
Countries: 
Publication: 
The International Journal of Tuberculosis and Lung Disease
Summary: 


Multidrug-resistant tuberculosis (MDR-TB) in children is a clinical entity that has been little studied. Our knowledge of the optimal way to diagnose and treat TB in children is largely derived from studies in adults, and therein lies the young children have different pathophysiologic manifestations of TB, different immune responses, different absorption, metabolism and excretion of antimycobacterial drugs, and different sensitivities to drug toxicity than adults. These factors make generalization from adult to pediatric TB treatment a highly speculative undertaking. In order to summarize what is known about pediatric MDRTB to highlight current research in this area and to outline an agenda for future research, Research Excellence to Stop TB Resistance (RESIST-TB) and the National Institutes of Health-funded International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) convened the Pediatric Multidrug-Resistant Tuberculosis Clinical Trials Landscape Meeting on 14 June 2016. This supplement summarizes the presentations from that meeting and provides a primer of current directions in this important research field.

Citation: 
Horsburgh, R.C.; Gupta, A. MDR-TB in children: back to the basics. International Journal of Tuberculosis and Lung Disease. 2018 May;22(Supp1):S1–S2.
Collaborators: 


Boston University School of Public Health and Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA